^
Association details:
| Biomarker: | EGFR L858R + EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1223P - Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)
Published date:
09/13/2021
Excerpt:
...pts with EGFRm+ NSCLC (Del19 or L858R) treated with 1st-line afa/2nd-line osi in regular clinical practice (n = 191; all T790M+)...ORR with afa and osi was 74% and 45%....These data support the previous GioTag study and show encouraging activity of sequential afa/osi in pts with EGFRm+ NSCLC and acquired T790M.
Trial ID:
Source:
Title:
Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study
Published date:
04/25/2020
Excerpt:
Group A complex u-EGFRm consisted of double mutations of G719X+E709F, G719X+S768I, G719X+L861Q, L858R+T790M, L858R+S768I, L858R+S765I, del19+S768I, del19+L747S, or R776C+L861Q...Response was significantly higher in groups A (70%) and C (54%) compared to B (13%; pairwise comparison P < .001 and .008, respectively)....In clinical practice, afatinib was active in patients with u-EGFRm NSCLC, particularly in complex and single mutations.
DOI:
10.1016/j.cllc.2020.04.011
Source:
Title:
Clinical activity of afatinib in a cohort of patients with lung adenocarcinoma harbouring uncommon EGFR mutations: A Spanish retrospective multicentre study
Published date:
05/16/2018
Excerpt:
U-EGFRm were analysed as complex mutations (Group A), Ins20 (Group B), or single mutations (Group C). Group A complex u-EGFRm consisted of double mutations of G719X+E709F, G719X+S768I, G719X+ L861Q, L858R+T790M, L858R+S768I, Del19+S768I, Del19+L747S, or R776C+L861Q. Response to afatinib was significantly higher in Group A and C (70% and 54%, respectively), compared with Group B (13%; pairwise comparison p < 0.001 and 0.013, respectively). Median OS for the entire cohort was 19.9 m (9.7-30.1). Hazard ratio for OS were 0.27 (95% CI 0.10-0-71, p = 0.009) and 0.40 (95% CI 0.17-0.95, p = 0.037) for Group A and C compared to Group B, respectively. afatinib was active in u-EGFRm NSCLC , particularly in complex and single mutations.
DOI:
10.1200/JCO.2018.36.15_suppl.e21028
